SCHEMBL4624847

SCHEMBL4624847

COC(=O)C(Cc1ccc2nc(-c3c(Cl)cccc3Cl)ccc2c1)C(=O)Nc1c(Cl)cccc1Cl

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB1 P05556 3/20 0.55
ITGAV P06756 1/20 0.55
ABL1 P00519 1/20 0.41
PPARG P37231 2/20 0.37
PPARD Q03181 2/20 0.37
PPARA Q07869 2/20 0.37
ITGA4 P13612 2/20 0.35
ITGB7 P26010 2/20 0.35
DGAT1 O75907 1/20 0.35
ALDH1A1 P00352 4/20 0.34
TP53 P04637 1/20 0.34
NLRP3 Q96P20 1/20 0.33
CTNNB1 P35222 1/20 0.33
KDM4E B2RXH2 3/20 0.33
HPGD P15428 2/20 0.33
MAPT P10636 2/20 0.32
POLB P06746 1/20 0.32
MAPK1 P28482 1/20 0.32
TYK2 P29597 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3321001 0.86 ITGB1 (0.60) ITGB1ITGAVABL1PPARGPPARD
SCHEMBL3314709 0.85 ITGB1 (0.63) ITGB1ITGAVABL1ITGA4ITGB7
SCHEMBL3313415 0.83 ITGB1 (0.59) ITGB1ITGAVABL1ITGA4ITGB7
SCHEMBL4750010 0.83 ITGB1 (0.59) ITGB1ITGAVABL1ITGA4ITGB7
SCHEMBL13398404 0.82 ITGB1 (0.64) ITGB1ITGAVABL1ITGA4ITGB7
SCHEMBL6156934 0.81 ITGB1 (0.51) ITGB1ITGAVABL1ITGA4ITGB7
SCHEMBL3314715 0.79 ITGB1 (0.61) ITGB1ITGAVABL1ITGA4ITGB7
SCHEMBL3316824 0.79 ITGB1 (0.56) ITGB1ITGAVABL1ITGA4ITGB7
SCHEMBL3319924 0.78 ITGB1 (0.80) ITGB1ITGAVITGA4ITGB7
SCHEMBL8351034 0.78 ITGB1 (0.60) ITGB1ITGAVABL1ITGA4ITGB7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501801-B1 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF VLA-4 DEPENDENT DISEASES UCB PHARMA SA (BE) 2008-01-23 EP disclosed
EP-1870402-A1 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as VLA-4 inhibitors UCB Pharma, S.A. (BE) 2007-12-26 EP disclosed